| Literature DB >> 28398755 |
Monika I Antczak1, Yongyou Zhang2, Changguang Wang1, Jennifer Doran1, Jacinth Naidoo1, Sukesh Voruganti1, Noelle S Williams1, Sanford D Markowitz2,3,4, Joseph M Ready1.
Abstract
The enzyme 15-prostaglandin dehydrogenase (15-PGDH) catalyzes the first step in the degradation of prostaglandins including PGE2. It is a negative regulator of tissue repair and regeneration in multiple organs. Accordingly, inhibitors of 15-PGDH are anticipated to elevate in vivo levels of PGE2 and to promote healing and tissue regeneration. The small molecule SW033291 (1) inhibits 15-PGDH with Ki = 0.1 nM in vitro, doubles PGE2 levels in vivo, and shows efficacy in mouse models of recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy. Here we describe optimized variants of 1 with improved solubility, druglike properties, and in vivo activity.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28398755 PMCID: PMC5580352 DOI: 10.1021/acs.jmedchem.7b00271
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446